自体CIK细胞维持治疗晚期非小细胞肺癌临床观察  

The use of autologous CIK cells in the maintenance treatment of advanced NSCLC

作　　者：邵青[1] 杨卫兵[1] 余丽梅[1] 章涛[1] 李宁[1] 柏玉举[1] 石磊[1] 岳国军[1] 张廷友[1] 郑召鹏[1] 黄丽斌[1] 

机构地区：[1]遵义医学院附属肿瘤医院,贵州遵义563003

出　　处：《西部医学》2011年第9期1641-1643,共3页Medical Journal of West China

基　　金：贵州省优秀科技教育人才省长专项资金项目(黔省专合字:2009-46号)

摘　　要：目的探讨自体CIK细胞对晚期非小细胞肺癌(Non-small cell lung cancer,NSCLC)维持治疗的临床效果。方法对16例晚期NSCLC患者在手术、放疗、化疗获益基础上,采用自体CIK进行维持治疗。结果患者使用自体CIK细胞治疗后,短期内生存质量有所提高,未发现严重毒副作用。结论自体CIK细胞治疗晚期非小细胞肺癌有控制肿瘤、增强患者免疫功能、改善生存质量(Quality of Life,QOL)以及延长生存期的趋势。Objective To observe the clinical efficacy of autologous cytokine-induced killer（CIK） cells in the maintenance treatment of advanced non-small-cell lung cancer（NSCLC）.Methods 16 advanced NSCLC patients after surgery,radiotherapy or chemotherapy were treated with autologous CIK cells.Results Patients treated with autologous CIK cells had an improvement of their quality of life and had no serious side-effect.Conclusion The use of autologous CIK cells to treat advanced NSCLC has advantages of enhancing immune function,improving the quality of life and prolonging overall survival.

关 键 词：自体CIK细胞 非小细胞肺癌 维持治疗 

分 类 号：R734.2[医药卫生—肿瘤]